Compare AbbVie Inc (ABBV) vs Medtronic PLC (MDT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Medtronic PLC — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Medtronic PLC trades at $82.5 (market cap $107.31B). The key difference: AbbVie Inc is far larger — about 4.2× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| ABBV | MDT | |
|---|---|---|
Market Cap | $449.91B | $107.31B |
Sector | Health | Health |
52-Week High | $261.07 | $105.35 |
52-Week Low | $184.85 | $73.75 |
Enterprise Value | $513.38B | $126.05B |
Dividend Yield | 2.72% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Medtronic (MDT) trades at $83.83, up 0.77% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company shows improving fundamentals with 2025 revenue of $33.54B and net income of $4.66B, supported by a 13.2% net margin. Recent acquisition of Scientia Vascular enhances its neurovascular portfolio, while analyst consensus remains strongly positive with a $98.77 price target.
MDT presents a compelling investment case with steady growth, a 3.5% dividend yield, and undervaluation relative to analyst targets. Key risks include rising debt levels and margin pressures from tariffs. The stock's current position near support levels offers a potential entry point for long-term investors seeking healthcare sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
